NO20070087L - Anti-IL-13 antistoffer, krystaller av anti-IL-13 antistoffer og komplekser omfattende dem - Google Patents

Anti-IL-13 antistoffer, krystaller av anti-IL-13 antistoffer og komplekser omfattende dem

Info

Publication number
NO20070087L
NO20070087L NO20070087A NO20070087A NO20070087L NO 20070087 L NO20070087 L NO 20070087L NO 20070087 A NO20070087 A NO 20070087A NO 20070087 A NO20070087 A NO 20070087A NO 20070087 L NO20070087 L NO 20070087L
Authority
NO
Norway
Prior art keywords
antibodies
crystals
polypeptide
complexes
antibody complexes
Prior art date
Application number
NO20070087A
Other languages
English (en)
Norwegian (no)
Inventor
Kevin D Parris
N N
Xiang-Yang Tan
Laura Long Lin
Amy Szepui Tam
Tania Shane
James M Wilhelm
Mark Stahl
Lidia Mosyak
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35503715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070087(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20070087L publication Critical patent/NO20070087L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20070087A 2004-06-09 2007-01-05 Anti-IL-13 antistoffer, krystaller av anti-IL-13 antistoffer og komplekser omfattende dem NO20070087L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57847304P 2004-06-09 2004-06-09
US57873604P 2004-06-09 2004-06-09
US58137504P 2004-06-22 2004-06-22
PCT/US2005/020334 WO2005121177A2 (en) 2004-06-09 2005-06-09 Anti-il-13 antibodies, crystals of anti-il-13 antibodies and complexes comprising them

Publications (1)

Publication Number Publication Date
NO20070087L true NO20070087L (no) 2007-01-05

Family

ID=35503715

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20070087A NO20070087L (no) 2004-06-09 2007-01-05 Anti-IL-13 antistoffer, krystaller av anti-IL-13 antistoffer og komplekser omfattende dem
NO20070133A NO20070133L (no) 2004-06-09 2007-01-08 Antistoffer mot human interleukin-13 og anvendelser derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20070133A NO20070133L (no) 2004-06-09 2007-01-08 Antistoffer mot human interleukin-13 og anvendelser derav

Country Status (19)

Country Link
US (2) US7615213B2 (de)
EP (3) EP2548889A1 (de)
JP (4) JP4970258B2 (de)
KR (3) KR20070034487A (de)
CN (2) CN102827280A (de)
AR (2) AR049390A1 (de)
AU (2) AU2005253981B2 (de)
BR (2) BRPI0511910A (de)
CA (2) CA2567081A1 (de)
CR (2) CR8783A (de)
EC (2) ECSP067072A (de)
IL (2) IL179093A0 (de)
MX (2) MXPA06014298A (de)
NO (2) NO20070087L (de)
NZ (1) NZ582046A (de)
RU (2) RU2006140096A (de)
SG (2) SG135207A1 (de)
TW (1) TWI391133B (de)
WO (2) WO2005121177A2 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
EP1444989A1 (de) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
DK3718564T3 (da) 2003-12-23 2023-11-06 Genentech Inc Nye anti-IL-13-antistoffer og anvendelser
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
MX2007005866A (es) 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
ES2412005T3 (es) * 2005-04-15 2013-07-09 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Tratamiento y prevención de la enfermedad intestinal inflamatoria que implica IL-13 y células NKT
AU2006296399B2 (en) 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
WO2007044450A2 (en) * 2005-10-06 2007-04-19 Baylor Research Institute Compositions and methods for the treatment of cancer
US20070202106A1 (en) * 2005-10-06 2007-08-30 Baylor Research Institute Compositions and methods for the treatment of cancer
US7910708B2 (en) * 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
SG2014013437A (en) 2005-11-30 2014-07-30 Abbott Lab Monoclonal antibodies and uses thereof
EP1962907A2 (de) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Proteinformulierungen mit verminderter viskosität und anwendungen davon
EA200801515A1 (ru) * 2006-01-24 2009-02-27 Домантис Лимитед Лиганды, которые связывают il-4 и/или il-13
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
CA2647846C (en) * 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
CN101529253A (zh) * 2006-06-21 2009-09-09 阿珀吉尼科斯有限公司 Il-4和/或il-10细胞因子在人癌症中的差异表达
EP2049147A2 (de) * 2006-07-06 2009-04-22 Apogenix GmbH Humane il-4-muteine in kombination mit chemotherapeutika oder pro-apoptotika in der krebstherapie
MX2009002554A (es) * 2006-09-08 2009-03-20 Abbott Lab Proteinas de enlace de interleucina-13.
US8350013B2 (en) 2006-09-08 2013-01-08 Wyeth Llc Arginine wash in protein purification using affinity chromatography
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP2010506839A (ja) * 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
EP1914242A1 (de) * 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
US8034906B2 (en) 2006-10-27 2011-10-11 Abbott Biotechnology Ltd. Crystalline anti-hTNFalpha antibodies
EP2089057A2 (de) * 2006-12-11 2009-08-19 Wyeth Verfahren und zusammensetzungen zur behandlung und überwachung der behandlung von mit il 13 assoziierten erkrankungen
US20090060906A1 (en) * 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
JP2010515774A (ja) 2007-01-16 2010-05-13 アボット・ラボラトリーズ 乾せんの治療方法
WO2008103473A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
SI2426144T1 (sl) * 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
CN101679507A (zh) * 2007-03-29 2010-03-24 艾博特公司 结晶抗人类il-12抗体
MX2009011366A (es) * 2007-04-23 2009-11-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13.
US7890055B1 (en) * 2007-07-09 2011-02-15 Everlokt Corporation Touch field compound field detector personal ID
CA2697163A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
EP2050764A1 (de) * 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
JP2009106163A (ja) * 2007-10-26 2009-05-21 Kyushu Univ 核酸配列、ベクター、形質転換体、製造方法、及び、核酸配列プライマー
US20110008345A1 (en) * 2007-11-30 2011-01-13 Claire Ashman Antigen-binding constructs
MY177564A (en) 2007-12-05 2020-09-20 Chugai Pharmaceutical Co Ltd Anti-nr10 antibody and use thereof
BRPI0908715A2 (pt) 2008-03-18 2016-05-03 Abbott Lab métodos para tratamento da psoríase
US8624002B2 (en) 2008-07-08 2014-01-07 Abbvie, Inc. Prostaglandin E2 binding proteins and uses thereof
BRPI0917370A2 (pt) 2008-08-20 2015-11-17 Centocor Ortho Biotech Inc anticorpos anti-il-13 manipulados, composições, métodos e usos.
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP2012508022A (ja) * 2008-11-06 2012-04-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 減少した免疫原性を有する操作された抗体および作製方法
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2409991B1 (de) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
BRPI1011145A2 (pt) 2009-05-15 2016-03-15 Chugai Pharmaceutical Co Ltd anticorpo anti-axl
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
ES2813398T3 (es) * 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
DK2560683T4 (da) 2010-04-23 2022-08-29 Hoffmann La Roche Fremstilling af heteromultimeriske proteiner
KR102099580B1 (ko) 2010-11-17 2020-04-10 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
CN105175542B (zh) 2010-12-16 2018-12-18 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
RU2013140685A (ru) 2011-02-04 2015-03-10 Дженентек, Инк. ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
BR112013021526B1 (pt) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
EP3235508B1 (de) 2011-03-16 2020-12-30 Sanofi Zubereitungen enthaltend ein antikörperähnliches protein mit dualer v-region
WO2013009521A2 (en) 2011-07-13 2013-01-17 Abbvie Inc. Methods and compositions for treating asthma using anti-il-13 antibodies
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2762493B1 (de) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
EP2866833B1 (de) 2012-06-27 2019-05-15 Merck Sharp & Dohme Corp. Kristalline antikörper gegen menschliches il-23
KR101521224B1 (ko) 2012-12-20 2015-05-19 한양대학교 산학협력단 T 세포 특이적인 인간화 단일조각항체 전달체
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
CN105307676A (zh) * 2013-04-05 2016-02-03 豪夫迈·罗氏有限公司 抗il-4抗体和双特异性抗体及其用途
MY176026A (en) 2013-09-13 2020-07-22 Genentech Inc Methods and composions comprising purified recombinant polypeptides
WO2015038884A2 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
MX2016003616A (es) 2013-09-27 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir heteromultimeros de polipeptidos.
WO2015061441A1 (en) 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
SG11201606870XA (en) 2014-02-21 2016-09-29 Genentech Inc Anti-il-13/il-17 bispecific antibodies and uses thereof
WO2015171822A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
ES2899894T3 (es) 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN114773469A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
CN107249637A (zh) 2015-02-27 2017-10-13 中外制药株式会社 用于治疗il‑6相关疾病的组合物
CN107430117A (zh) 2015-03-16 2017-12-01 豪夫迈·罗氏有限公司 检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
EP3279216A4 (de) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptid-hetero-oligomer
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
BR112018068363A2 (pt) 2016-03-14 2019-01-15 Chugai Pharmaceutical Co Ltd fármaco terapêutico indutor de dano celular para uso em terapia de câncer
DK3448391T3 (da) 2016-04-27 2024-06-24 Abbvie Mfg Management Unlimited Company Fremgangsmåder til behandling af sygdomme med skadelig il-13-aktivitet under anvendelse af anti-il-13-antistoffer
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
DK3528838T5 (da) 2016-09-23 2024-09-02 Hoffmann La Roche Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis
CN108367075B (zh) 2016-11-23 2022-08-09 免疫方舟医药技术股份有限公司 4-1bb结合蛋白及其用途
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3565520A4 (de) 2017-01-06 2020-08-19 Palvella Therapeutics, Inc. Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN109776677B (zh) * 2017-11-15 2023-11-03 尚华科创投资管理（江苏）有限公司 一种人源化抗il-13抗体及其制备方法和应用
BR112020016172A2 (pt) 2018-02-09 2020-12-15 Genentech, Inc. Métodos de tratamento, métodos para determinar, métodos para selecionar uma terapia, métodos para avaliar uma resposta e monitorar a resposta, kits para identificar um paciente, agentes selecionados, agentes para uso, uso de um agente selecionado e uso de um antagonista
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
BR112020017715A2 (pt) 2018-03-16 2020-12-29 Zoetis Services Llc Vacinas de peptídeo contra interleucina-31
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
EP3883634A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
EP3941589A1 (de) 2019-03-21 2022-01-26 Regeneron Pharmaceuticals, Inc. Kombination von il-4/il-13-signalweginhibitoren und plasmazellablation zur behandlung von allergie
WO2020197502A1 (en) * 2019-03-26 2020-10-01 Aslan Pharmaceuticals Pte Ltd Treatment employing anti-il-13r antibody or binding fragment thereof
EP3870261B1 (de) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Einnehmbare vorrichtung zur abgabe eines therapeutischen mittels an den magen-darm-trakt
CN118530356A (zh) * 2020-12-08 2024-08-23 深圳福沃药业有限公司 抗il-13抗体及其用途
CA3208011A1 (en) 2021-03-17 2022-09-22 Sarah Harris Methods of treating atopic dermatitis with anti il-13 antibodies
IL311027A (en) 2021-09-15 2024-04-01 Dermira Inc IL-13 inhibitors for the treatment of PRURIGO NODULARIS
KR20240101681A (ko) 2021-11-17 2024-07-02 디스크 메디슨, 인크. 신장 질환에 의한 빈혈을 치료하는 방법
WO2024182714A1 (en) 2023-03-02 2024-09-06 Alloy Therapeutics, Inc. Anti-cd22 antibodies and uses thereof

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) * 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
WO1991009059A1 (en) 1989-12-20 1991-06-27 Schering Corporation Antibody antagonists of human interleukin-4
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
ATE130869T1 (de) 1991-03-29 1995-12-15 Sanofi Sa Protein mit der aktivität vom typ von cytokin, dafür kodierende rekombinante dns, transformierte zellen und mikroorganismen.
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
JPH07508179A (ja) 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
EP0604693A1 (de) 1992-12-29 1994-07-06 Schering-Plough Monoklonale Antikörper gegen den menschlichen Interleukin-4-Rezeptor und Hybridomen die diese produzieren
WO1995006666A1 (en) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anti-gp39 antibodies and uses therefor
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
EP0659766A1 (de) 1993-11-23 1995-06-28 Schering-Plough Menschliche Monoklonalantikörper gegen menschliche Cytokine und Verfahren zur Herstellung dieser Antikörper
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20010053371A1 (en) 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
JP4224135B2 (ja) 1995-10-23 2009-02-12 ズィナイス セラピューティックス ピーティーワイ．エルティーディー． 新規なヘモポエチン受容体およびそれをコードする遺伝子配列
US6911530B1 (en) * 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US7078494B1 (en) * 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
WO1997033913A1 (en) 1996-03-13 1997-09-18 Zymogenetics, Inc. Cytokine-receptor expressed in testis cells
AU6450196A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
AU6175696A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
EP0812913A3 (de) 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR1 Rezeptor, ein Rezeptor der Zytokinrezeptor-Familie
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
TR200001246T2 (tr) 1997-01-10 2000-07-21 Biogen,Inc. Anti-CD40L bileşikleri ile lupus nefritis tedavisi
US6387615B2 (en) 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
EP1141286B1 (de) * 1998-12-14 2006-10-18 Genetics Institute, LLC Cytokinrezeptor-kette
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008173A (pt) 1999-02-10 2002-10-22 Welfide Corp Composto de amida e seu uso como campo técnico de medicina da invenção
WO2000078336A1 (en) 1999-06-21 2000-12-28 Genetics Institute, Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
AU2000278349A1 (en) 1999-09-28 2001-04-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 13 gene
AU7863900A (en) 1999-10-06 2001-05-10 Penn State Research Foundation, The Il13 mutants
GB0004016D0 (en) * 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
AU2001253282A1 (en) * 2000-04-07 2001-10-23 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
EP2990420B1 (de) 2000-05-26 2016-12-21 Immunex Corporation Verwendung von interleukin-4 rezeptor antikörpern und zusammensetzungen davon
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
AU2002243443A1 (en) 2000-10-20 2002-07-24 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
JP4731793B2 (ja) * 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
US6649935B2 (en) 2001-02-28 2003-11-18 International Business Machines Corporation Self-aligned, planarized thin-film transistors, devices employing the same
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US7216242B2 (en) * 2001-03-16 2007-05-08 Dualcor Technologies, Inc. Personal electronics device with appliance drive features
AUPR544401A0 (en) * 2001-06-04 2001-06-28 Bischof, Robert Juergen Animal model for allergy
JP2005506960A (ja) * 2001-06-07 2005-03-10 ワイエス Ｉｌ−１３の溶液構造およびこの使用
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20030023555A1 (en) * 2001-07-26 2003-01-30 Cashworks, Inc. Method and system for providing financial services
JP2005522986A (ja) 2001-10-19 2005-08-04 ジェネンテック・インコーポレーテッド 炎症性腸疾患の診断と治療のための組成物と方法
US20040248260A1 (en) * 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
CA2464695A1 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
US20040234499A1 (en) 2001-10-26 2004-11-25 David Shealy Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
CA2468950A1 (en) * 2001-11-27 2003-06-05 Mochida Pharmaceutical Co., Ltd. Anti-il13 receptor .alpha.1 neutralizing antibody
WO2003047632A1 (en) * 2001-12-04 2003-06-12 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Chimeric molecule for the treatment of th2-like cytokine mediated disorders
EP1325868A1 (de) 2002-01-08 2003-07-09 Tetra Laval Holdings & Finance SA Verpackungsmaschine zum kontinuierlichen Herstellen von versiegelten Verpackungen fliessfähiger Nahrungsmittel aus schlauchförmigem Verpackungsmaterial
JP4432031B2 (ja) * 2002-03-22 2010-03-17 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
CA2480777A1 (en) 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
JP4689268B2 (ja) 2002-06-14 2011-05-25 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｉｌ−１３およびｎｋ−ｔ細胞に関する、結腸炎を処置および予防する方法
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
WO2004039956A2 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2179742A1 (de) 2002-11-26 2010-04-28 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
CN100434440C (zh) 2002-12-02 2008-11-19 阿布格尼克斯公司 针对肿瘤坏死因子的抗体及其用途
EP1444989A1 (de) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
EP1651266B1 (de) 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005042028A2 (en) 2003-10-27 2005-05-12 Neopharm, Inc. Il-13 conjugated to an immunogen and uses thereof
DK3718564T3 (da) 2003-12-23 2023-11-06 Genentech Inc Nye anti-IL-13-antistoffer og anvendelser
RU2006126704A (ru) * 2003-12-24 2008-01-27 Уайт (Us) Способы лечения астмы
WO2005079755A2 (en) 2004-02-12 2005-09-01 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US20050266005A1 (en) * 2004-02-27 2005-12-01 Heavner George A Methods and compositions for treating IL-3 related pathologies
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
EP2089057A2 (de) 2006-12-11 2009-08-19 Wyeth Verfahren und zusammensetzungen zur behandlung und überwachung der behandlung von mit il 13 assoziierten erkrankungen
MX2009011366A (es) 2007-04-23 2009-11-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13.

Also Published As

Publication number Publication date
BRPI0511910A (pt) 2007-08-14
CA2567081A1 (en) 2005-12-22
ECSP067073A (es) 2007-01-26
WO2005123126A3 (en) 2007-07-12
JP4970258B2 (ja) 2012-07-04
KR20070022309A (ko) 2007-02-26
AU2005253981A1 (en) 2005-12-29
KR20130103735A (ko) 2013-09-24
EP1765401A2 (de) 2007-03-28
AU2005253981B2 (en) 2011-10-13
CR8784A (es) 2007-10-04
WO2005121177A3 (en) 2006-06-22
JP2015037401A (ja) 2015-02-26
EP2548889A1 (de) 2013-01-23
AR077931A2 (es) 2011-10-05
CN101141980A (zh) 2008-03-12
BRPI0510881A (pt) 2007-12-26
ECSP067072A (es) 2007-05-30
IL179476A0 (en) 2007-05-15
IL179476A (en) 2015-06-30
EP1765401A4 (de) 2010-02-10
SG155260A1 (en) 2009-09-30
TW200612908A (en) 2006-05-01
JP2011155980A (ja) 2011-08-18
KR101299073B1 (ko) 2013-08-27
NZ582046A (en) 2011-07-29
TWI391133B (zh) 2013-04-01
WO2005123126A2 (en) 2005-12-29
KR101462878B1 (ko) 2014-11-18
CN102827280A (zh) 2012-12-19
IL179093A0 (en) 2007-03-08
CA2567129A1 (en) 2005-12-29
MXPA06014298A (es) 2007-02-19
US7615213B2 (en) 2009-11-10
KR20070034487A (ko) 2007-03-28
US8221752B2 (en) 2012-07-17
SG135207A1 (en) 2007-09-28
CR8783A (es) 2007-06-08
US20060063228A1 (en) 2006-03-23
EP1756161A2 (de) 2007-02-28
RU2006140096A (ru) 2008-07-20
JP2008515776A (ja) 2008-05-15
CN101141980B (zh) 2012-10-31
US20100129360A1 (en) 2010-05-27
NO20070133L (no) 2007-01-08
WO2005121177A2 (en) 2005-12-22
RU2427589C2 (ru) 2011-08-27
AR049390A1 (es) 2006-07-26
AU2005252700A1 (en) 2005-12-22
RU2006140793A (ru) 2008-07-20
MXPA06014299A (es) 2007-02-19
JP2008502366A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
NO20070087L (no) Anti-IL-13 antistoffer, krystaller av anti-IL-13 antistoffer og komplekser omfattende dem
NO20071717L (no) Anti-Fc-gamma-RIIB-reseptorantistoff og anvendelser av dette
ATE475673T1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
NO20070153L (no) Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
CY1110843T1 (el) Αντισωματα εναντι il-22ra και εταιροι δεσμευσης και μεθοδοι χρησης σε φλεγμονη
NO20062148L (no) Antistoffer som binder interleukin-4-reseptor
NO20071788L (no) Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav.
ATE465181T1 (de) Humanisierte anti-cmet-antagonisten
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
NO20063026L (no) Antistoffer
NO20045645L (no) Noytraliserende humant anti-IGFR-antistoff
NZ588674A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
ATE444308T1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
WO2003078468A3 (de) Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung
DK1572748T3 (da) Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
WO2004029092A3 (fr) Anticorps pour adcc et induisant la production de cytokines.
Leclercq et al. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors
ATE414534T1 (de) Immunotherapeutische methoden und systeme
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
ATE363531T1 (de) Claudin polypeptide
DK1565491T3 (da) Antistoffer, der binder til human magic roundabout (MR), polypeptider og anvendelser deraf til inhibering af angiogenese

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application